Taken together, these data emphasize a complex interplay between PD-1, PD-L1, and ischemic heart disease, and suggest that therapeutic modulation of these immune checkpoint pathways could represent a promising strategy for the prevention and treatment of cardiovascular disorders. This evidence concerns the gene PDCD1 and coronary artery disorder.